EP3790545A4 - Verfahren und zusammensetzungen zur behandlung von sichelzellanämie und thalassämie - Google Patents

Verfahren und zusammensetzungen zur behandlung von sichelzellanämie und thalassämie Download PDF

Info

Publication number
EP3790545A4
EP3790545A4 EP19742516.8A EP19742516A EP3790545A4 EP 3790545 A4 EP3790545 A4 EP 3790545A4 EP 19742516 A EP19742516 A EP 19742516A EP 3790545 A4 EP3790545 A4 EP 3790545A4
Authority
EP
European Patent Office
Prior art keywords
thalassemia
compositions
treatment
methods
sickle cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19742516.8A
Other languages
English (en)
French (fr)
Other versions
EP3790545A1 (de
Inventor
Yutaka Niihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emmaus Medical Inc
Original Assignee
Emmaus Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emmaus Medical Inc filed Critical Emmaus Medical Inc
Publication of EP3790545A1 publication Critical patent/EP3790545A1/de
Publication of EP3790545A4 publication Critical patent/EP3790545A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19742516.8A 2019-07-17 2019-07-17 Verfahren und zusammensetzungen zur behandlung von sichelzellanämie und thalassämie Withdrawn EP3790545A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/000033 WO2021010937A1 (en) 2019-07-17 2019-07-17 Methods and compositions for the treatment of sickle cell diseases and thalassemia

Publications (2)

Publication Number Publication Date
EP3790545A1 EP3790545A1 (de) 2021-03-17
EP3790545A4 true EP3790545A4 (de) 2021-07-28

Family

ID=74210735

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19742516.8A Withdrawn EP3790545A4 (de) 2019-07-17 2019-07-17 Verfahren und zusammensetzungen zur behandlung von sichelzellanämie und thalassämie

Country Status (2)

Country Link
EP (1) EP3790545A4 (de)
WO (1) WO2021010937A1 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693671A (en) * 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
WO2013095681A1 (en) * 2011-12-19 2013-06-27 Emmaus Medical, Inc. Methods and compositions for the treatment of diverticulosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375994B1 (en) * 1999-08-20 2002-04-23 Sun Ten Laboratories, Inc. Preparation of fiber, L-glutamine and a soy derivative for the purpose of enhancement of isoflavone bioavailability
PT2662091T (pt) 2006-12-01 2018-12-03 Novartis Ag Anticorpos anti-p-selectina e métodos para os utilizar no tratamento de doenças inflamatórias
US20090306209A1 (en) * 2008-06-04 2009-12-10 Daugherty F Joseph Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
WO2013057592A2 (en) 2011-09-14 2013-04-25 King Abdullah University Of Science And Technology Treatment of sickle cell disease
EP3099334B1 (de) 2014-01-30 2019-07-31 Children's Hospital Medical Center Verbessertes fetales hämoglobin zur genetischen korrektur von sichelzellanämie
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693671A (en) * 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
WO2013095681A1 (en) * 2011-12-19 2013-06-27 Emmaus Medical, Inc. Methods and compositions for the treatment of diverticulosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021010937A1 *

Also Published As

Publication number Publication date
EP3790545A1 (de) 2021-03-17
WO2021010937A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
EP3464381A4 (de) Verbindungen und verfahren zur behandlung von trop2-positiven erkrankungen
EP3934652A4 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von krankheiten
EP3716767A4 (de) Verfahren und zusammensetzungen zur behandlung von seltenen erkrankungen
EP3866781A4 (de) Neuartige zusammensetzung zur behandlung von entzündlichen erkrankungen
EP4031152A4 (de) Verfahren und probiotische zusammensetzungen zur behandlung von stoffwechselerkrankungen und -störungen
EP3906043A4 (de) Verfahren und zusammensetzungen zur behandlung von morbus fabry
EP3826666A4 (de) Zusammensetzungen und verfahren zur behandlung von nrp2-assoziierten erkrankungen
EP3790563A4 (de) Zusammensetzung zur behandlung von hautleiden
EP3969597A4 (de) Zusammensetzungen und verfahren zur behandlung von atpase-vermittelten erkrankungen
EP3784260A4 (de) Zusammensetzung zur behandlung von hautleiden
EP3761970A4 (de) Zusammensetzungen und verfahren zur behandlung von neurologischen erkrankungen
EP3775263A4 (de) Zusammensetzungen und verfahren zur behandlung von akne
EP3818081A4 (de) Zusammensetzungen und verfahren zur behandlung von erkrankungen oder störungen im zusammenhang mit inflammasom
EP3863630A4 (de) Zusammensetzungen und verfahren zur behandlung von presbyopie
EP3955937A4 (de) Verbindungen und zusammensetzungen zur behandlung von augenkrankheiten
EP4007764A4 (de) Menschliche aminosterin-ent-03-verbindungen, diese enthaltende zusammensetzungen und verfahren zu ihrer verwendung
EP3737379A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechselkrankheiten
EP3935078A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von retinopathien
EP3930704A4 (de) Zusammensetzungen mit zimtsäure und verfahren zur herstellung davon
EP3955926A4 (de) Verbindungen und zusammensetzungen zur behandlung von augenkrankheiten
EP4034109A4 (de) Verfahren und zusammensetzung zur behandlung von erkrankungen
EP3866786A4 (de) Zusammensetzungen und verfahren zur unterdrückung und/oder behandlung von stoffwechselerkrankungen und/oder eines klinischen zustands davon
EP3846843A4 (de) Zusammensetzungen und verfahren zur behandlung von herzerkrankungen
EP3877383A4 (de) Verbindungen und zusammensetzungen zur behandlung von atemwegserkrankungen
EP3813872A4 (de) Zusammensetzung zur behandlung von hautleiden

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190801

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20210625

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/365 20060101AFI20210621BHEP

Ipc: A61K 31/551 20060101ALI20210621BHEP

Ipc: A61K 45/06 20060101ALI20210621BHEP

Ipc: A61P 7/06 20060101ALI20210621BHEP

Ipc: A61K 31/198 20060101ALI20210621BHEP

Ipc: A61K 31/716 20060101ALI20210621BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240201